Intranasal vaccine

Discovery of novel protein antigens using whole genome based antigen discovery tools (Tn-Seq and Genomic Array Footprinting). Antigen fragments are delivered using outer membrane vesicles (OMVs), which induce strong immune responses and protection against carriage .Administration is intranasal and strong protection is achieved in a mouse mode.

Applications

• Broad protection against Streptococcus pneumoniae infections in children and elderly
• Reduction of carriage > reduction of transmission
• Affordable needle free and easy to apply: intranasal delivery

Development status

Patent filed and 2 patents pending. We have proof of concept in mice and are working on lead optimization in pre-clinical studies and in parallel work on the scale up of manufacturing under GMP. In collaboration with experts we are currently testing spray devices for delivery of the OMV containing pneumococcal antigens. The clinical phase I study is in preparation.

Opportunity

• Out-licensing
• Development collaboration from clinical phase IIa

Contact

For more information contact us through businessdevelopment@radboudumc.nl.